New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:07 EDTINSYInsys receives FDA orphan drug designation for pharmaceutical cannabidiol
Insys Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its pharmaceutical cannabidiol for the treatment of Lennox-Gastaut Syndrome, a rare pediatric-onset epilepsy. The company said, "We have the unique opportunity to test a controlled pharmaceutical CBD product for Lennox-Gastaut Syndrome, and our company is committed to advancing cannabinoid therapies that have the potential to provide significant medical benefits to patients across multiple indications. We expect to file an Investigational New Drug Application for CBD in 2H14."
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
08:52 EDTINSYInsys Therapeutics price target raised to $46 from $38 at Piper Jaffray
Subscribe for More Information
June 25, 2015
11:09 EDTINSYInsys sinks after nurse pleads guilty to receiving kickbacks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use